Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Imatinib spells BAD news for Bcr/abl-positive leukemias.

× No keyword cloud information.

26 in total

1. High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML.

Authors: Thoralf Lange; Christine Günther; Thomas Köhler; Rainer Krahl; Scarlet Musiol; Sabine Leiblein; Haifa-Kathrin Al-Ali; Iris van Hoomissen; Dietger Niederwieser; Michael W N Deininger
Journal: Blood Date: 2002-10-24 Impact factor: 22.113

2. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.

Authors: Junya Kuroda; Hamsa Puthalakath; Mark S Cragg; Priscilla N Kelly; Philippe Bouillet; David C S Huang; Shinya Kimura; Oliver G Ottmann; Brian J Druker; Andreas Villunger; Andrew W Roberts; Andreas Strasser
Journal: Proc Natl Acad Sci U S A Date: 2006-09-22 Impact factor: 11.205

3. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs.

Authors: G Fang; C N Kim; C L Perkins; N Ramadevi; E Winton; S Wittmann; K N Bhalla
Journal: Blood Date: 2000-09-15 Impact factor: 22.113

4. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.

Authors: Ravi Bhatia; Melissa Holtz; Ning Niu; Rachel Gray; David S Snyder; Charles L Sawyers; Daniel A Arber; Marilyn L Slovak; Stephen J Forman
Journal: Blood Date: 2003-02-06 Impact factor: 22.113

5. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib.

Authors: Amie S Corbin; Paul La Rosée; Eric P Stoffregen; Brian J Druker; Michael W Deininger
Journal: Blood Date: 2003-02-06 Impact factor: 22.113

6. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.

Authors: Neil P Shah; John M Nicoll; Bhushan Nagar; Mercedes E Gorre; Ronald L Paquette; John Kuriyan; Charles L Sawyers
Journal: Cancer Cell Date: 2002-08 Impact factor: 31.743

Review 7. Specific targeted therapy of chronic myelogenous leukemia with imatinib.

Authors: Michael W N Deininger; Brian J Druker
Journal: Pharmacol Rev Date: 2003-07-17 Impact factor: 25.468

Review 8. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias.

Authors: Neil P Shah; Charles L Sawyers
Journal: Oncogene Date: 2003-10-20 Impact factor: 9.867

9. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL.

Authors: M Horita; E J Andreu; A Benito; C Arbona; C Sanz; I Benet; F Prosper; J L Fernandez-Luna
Journal: J Exp Med Date: 2000-03-20 Impact factor: 14.307

Imatinib spells BAD news for Bcr/abl-positive leukemias.

1. High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML.

2. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.

3. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs.

4. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.

5. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib.

6. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.

Review 7. Specific targeted therapy of chronic myelogenous leukemia with imatinib.

Review 8. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias.

9. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL.

10. FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons.

1. Bcl2 is not required for the development and maintenance of leukemia stem cells in mice.

2. Loss of Bcl-x in Ph+ B-ALL increases cellular proliferation and does not inhibit leukemogenesis.

3. Essential role for telomerase in chronic myeloid leukemia induced by BCR-ABL in mice.